Molecule News and Research

RSS

Defective calcium metabolism in nerve cells contributes to neurological disorder

Defective calcium metabolism in nerve cells may play a major role in a fatal genetic neurological disorder that resembles Huntington's disease, researchers at UT Southwestern Medical Center have found in a mouse study.

26 Nov 2008

MorphoSys and Galapagos enter alliance to co-develop novel therapeutic antibodies in bone and joint disease

MorphoSys AG and Galapagos NV announced today the launch of a long term co-development alliance aimed at discovering and developing antibody therapies based on novel modes of action in bone and joint disease, including rheumatoid arthritis, osteoporosis and osteoarthritis.

26 Nov 2008

Scientists create synthetic Heparin in more varieties

Scientists at the University of North Carolina at Chapel Hill have learned to customize a key human enzyme responsible for producing heparin, opening the door to a more effective synthetic anticoagulant as well as treatments for other conditions.

25 Nov 2008

Peregrine Pharmaceuticals awarded U.S. patent for anti-viral applications of phospholipid-targeting antibodies

Peregrine Pharmaceuticals, Inc. has announced that the U.S. Patent and Trademark Office has issued U.S. Patent Number No. 7,455,833, which includes broad claims covering anti-viral applications of antibodies that directly bind to aminophospholipids.

25 Nov 2008

Scientists develop peptide that converts Bcl-2 protein from a cancer cell's friend to a foe

If you're a cancer cell, you want a protein called Bcl-2 on your side because it decides if you live or die.

25 Nov 2008

MorphoSys granted U.S. patent on antibodies against GM-CSF to treat inflammatory disorders

MorphoSys AG and the University of Melbourne announced today that the U.S. Patent & Trademark Office (USPTO) has confirmed that it will issue U.S. Patent No. 7,455,836, covering key uses of antibodies against GM-CSF.

25 Nov 2008

Researchers develop new strategy for broad spectrum anti-viral drugs

Bavituximab, an anti-viral drug developed by UT Southwestern Medical Center researchers, shows promise as a new strategy to fight viral diseases, including potential bioterrorism agents.

24 Nov 2008

Scientists shed light on how DNA is unwound so that its code can be read

Researchers at The Scripps Research Institute have figured out how a macromolecular machine is able to unwind the long and twisted tangles of DNA within a cell's nucleus so that genetic information can be "read" and used to direct the synthesis of proteins, which have many specific functions in the body.

24 Nov 2008

Discovery of novel drug target for chronic lymphocytic leukemia

Researchers at the University of California, San Diego (UCSD) and the Moores UCSD Cancer Center have discovered what could be a novel drug target for an often difficult-to-treat form of leukemia.

24 Nov 2008

FDA accepts filing and grants priority review for DX-88 for hereditary angioedema

Dyax Corp. has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's Biologics License Application (BLA) for DX-88 (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) and has designated the application for Priority Review.

21 Nov 2008

Does hormone treatment predispose patients to breast cancer?

Breast cancer, the leading cause of death among women in France, is the most commonly occurring cancer in women.

21 Nov 2008

New insight into the events that prime the uterine muscles for contraction

During pregnancy, the muscles of the uterus are relatively inactive.

20 Nov 2008

Lactic acid found to be important energy source for tumor cells

Many tumors have cells that burn fuel for activities in different ways. Tumor cells near blood vessels have adequate oxygen sources and can either burn glucose like normal cells, or lactic acid (lactate). Tumor cells further from vessels are hypoxic and inefficiently burn a lot of glucose to keep going. In turn, they produce lactate as a waste product.

20 Nov 2008

New compounds break up cancer-causing protein STAT3 and destroy breast cancer tumors.

Two new compounds created by a University of Central Florida professor show early promise for destroying breast cancer tumors.

19 Nov 2008

Scientists gain new insights into regulation of calpains

Scientists at St. Jude Children's Research Hospital have gained new insights into regulation of one of the body's enzyme workhorses called calpains.

19 Nov 2008

Breakthrough could revolutionise drug development

Scientists in Leeds have devised a new way to create the next generation of man-made molecules in a breakthrough that could revolutionise drug development.

19 Nov 2008

Amgen, Takeda and Millennium update on phase 3 trial of Motesanib in non-small cell lung cancer

Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.

19 Nov 2008

Scientists discover new compounds to target muscular dystrophy

Using a drug-discovery technique in which molecules compete against each other for access to the target - the strand of toxic RNA that causes the most common form of muscular dystrophy in adults - a team at the University of Rochester Medical Center has identified several compounds that, in the laboratory, block the unwanted coupling of two molecules that is at the root of the disease.

19 Nov 2008

Nontoxic nanoparticle delivers and tracks drugs

A nontoxic nanoparticle developed by Penn State researchers is proving to be an all-around effective delivery system for both therapeutic drugs and the fluorescent dyes that can track their delivery.

18 Nov 2008

New imaging technique tracks cancer-killing cells over prolonged period

Coaxing a patient's own cells to hunt down and tackle infected or diseased cells is a promising therapeutic approach for many disorders.

18 Nov 2008

Molecule News and Research

Defective calcium metabolism in nerve cells contributes to neurological disorder

MorphoSys and Galapagos enter alliance to co-develop novel therapeutic antibodies in bone and joint disease

Scientists create synthetic Heparin in more varieties

Peregrine Pharmaceuticals awarded U.S. patent for anti-viral applications of phospholipid-targeting antibodies

Scientists develop peptide that converts Bcl-2 protein from a cancer cell's friend to a foe

MorphoSys granted U.S. patent on antibodies against GM-CSF to treat inflammatory disorders

Researchers develop new strategy for broad spectrum anti-viral drugs

Scientists shed light on how DNA is unwound so that its code can be read

Discovery of novel drug target for chronic lymphocytic leukemia

FDA accepts filing and grants priority review for DX-88 for hereditary angioedema

Does hormone treatment predispose patients to breast cancer?

New insight into the events that prime the uterine muscles for contraction

Lactic acid found to be important energy source for tumor cells

New compounds break up cancer-causing protein STAT3 and destroy breast cancer tumors.

Scientists gain new insights into regulation of calpains

Breakthrough could revolutionise drug development

Amgen, Takeda and Millennium update on phase 3 trial of Motesanib in non-small cell lung cancer

Scientists discover new compounds to target muscular dystrophy

Nontoxic nanoparticle delivers and tracks drugs

New imaging technique tracks cancer-killing cells over prolonged period

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News